Vistagen Therapeutics Inc (NAS:VTGN)
$ 3.19 0.04 (1.27%) Market Cap: 86.31 Mil Enterprise Value: -21.37 Mil PE Ratio: 0 PB Ratio: 0.81 GF Score: 29/100

Q4 2022 VistaGen Therapeutics Inc Earnings Call Transcript

Jun 23, 2022 / 09:00PM GMT
Release Date Price: $31.2 (+1.96%)
Operator

Greetings. Welcome to the VistaGen Therapeutics 2022 Fiscal Year End Results Conference Call. (Operator Instructions) A question-and-answer session will follow the formal presentation. (Operator Instructions) Please note that this conference is being recorded.

I will now turn the conference over to your host, Mark Flather, Vice President of Investor Relations for VistaGen. You may begin.

Mark Flather
VistaGen Therapeutics, Inc. - VP of IR

Thank you, Kyle. Hello, and welcome to VistaGen's conference call covering our fiscal year 2022 financial results, recent accomplishments and anticipated milestones. I'm Mark Flather, Vice President of Investor Relations at VistaGen. Thank you for joining us today, and welcome to our stockholders, analysts and anyone taking an interest in VistaGen.

Joining me today are Shawn Singh, our Chief Executive Officer; Jerry Dotson, our Chief Financial Officer; and Dr. Mark Smith, our Chief Medical Officer. Format of this call, as Kyle mentioned, will be -- will consist of prepared remarks from management, followed

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot